ABT News 38.93 Abbott Laboratories (ABT)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Abbott Laboratories (ABT) 38.93 $ABT

Earnings Roundup: Look Beyond Abbott Labs' Short-term Bumps
Todd Campbell, The Motley Fool - Motley Fool - Sun Apr 20, 9:00AM CDT
Sales across Abbott Labs '   four major business units grew less than 1% last quarter versus the same period a year ago. When including currency conversion headwinds, sales actually fell -2.5% in the past year. However, investors may want to look...

Company News for April 17, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 9:06AM CDT
Companies in the News are: BAC,IBKR,STJ,ABT

Research and Markets: Global Drug-Eluting Stent Market 2014-2018 With Abbott Laboratories, Boston Scientific, Medtronic & Terumo Dominating
Business Wire - Thu Apr 17, 6:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bj54l9/global) has announced the addition of the "Global Drug-eluting Stent Market 2014-2018 with Abbott Laboratories, Boston Scientific, Medtronic & Terumo Dominating" report to their offering.

Global Drug-eluting Stent Market 2014-2018 with Abbott Laboratories, Boston Scientific, Medtronic & Terumo Dominating
M2 - Thu Apr 17, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c6b9zf/global) has announced the addition of the "Global Drug-eluting Stent Market 2014-2018 with Abbott Laboratories, Boston Scientific, Medtronic & Terumo Dominating" report to their offering. One of the key drivers is the increase in the number of patients suffering from CVD. An unhealthy diet and lack of physical activity are the major factors leading to the increase in the number of people prone to CVD. Increasing demand for minimally-invasive procedures has been witnessed among members of the rapidly aging population across the world, and this is expected to boost the growth of the Global DES market. In addition, the cost efficiencies offered by less invasive methods are likely to increase the demand for the procedures in the near future. Minimally-invasive endovascular procedures are surgeries performed through minute incisions in the body. Such procedures can be used to treat plaque blockages in the arteries of the heart and other vessel walls of peripheral organs such as the kidneys and the brain. The principal advantages of these procedures over conventional surgeries are the short recovery time, the short length of the scars resulting in less physical trauma, low risk of infection, and minimized bleeding, and the shorter hospital stays associated with these surgeries. Further, the report states that the biggest challenge the market is facing is the decline in the ASP of DESs. There has been a steady decline in the prices of DESs worldwide because of the increased competition and the high rate of adoption. The reduction in the ASP has a negative impact on the overall market revenue. Key vendors dominating this space are: - Abbott Laboratories - Boston Scientific Corp - Medtronic Inc. - Terumo Corp. Other vendors mentioned in the report are: - B. Braun Melsungen AG - Biosensors International Ltd - BIOTRONIK SE & Co. KG - Cook Medical Inc. - Lepu Medical Technology Co. Ltd - MicroPort Scientific Corp. - Sorin Group USA Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Types of Drugs - Geographical Segmentation - Key Leading Countries - Rate of Incidence and Prevalence - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/c6b9zf/global

Abbott Labs Q1 sales, EPS fall
at Investor's Business Daily - Wed Apr 16, 5:46PM CDT
The medical-products giant reported a 2.4% fall in EPS to 41 cents, beating views by 5 cents. Revenue dipped 2.5% to $5.24 bil, slightly below views for $5.27 bil. Baby-formula sales plunged 7% to $909 mil from the lingering effects of a recall in...

Abbott Labs Earnings: Still Marking Time
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Apr 16, 5:30PM CDT
Like many other large med-tech companies, Abbott Labs remains an exercise in frustration right now. There are pressures throughout most of the company's business lines, with only the diagnostics business really showing much growth. Although...

Abbott Laboratories Set to Possibly Pullback After Yesterday's Rally of 1.08%
Comtex SmarTrend(R) - Wed Apr 16, 4:36PM CDT
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $37.56 to a high of $38.90. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of $38.06 on volume of 10.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Abbott Labs Tops Earnings, Misses Sales Est - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 11:41AM CDT
Abbott Laboratories reported first quarter 2014 earnings of 41 cents per share, above the Zacks Consensus Estimate of 35 cents.

Abbott Q1 Performance Slips, But EPS Tops Estimates
at Investor's Business Daily - Wed Apr 16, 11:00AM CDT
Abbott Laboratories' (ABT) first-quarter revenue and earnings dipped, but earnings still topped analyst estimates, sending shares slightly higher Wednesday. The medical products giant reported a 2.4% fall in earnings to 41 cents per share. But this...

Prestige Brands Gains on Product Acquisition News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 10:40AM CDT
Prestige Brands announced that it has signed a purchase agreement with Australia-based The Hydration Pharmaceuticals Trust of Victoria to acquire their over-the-counter (OTC) oral rehydration brand, Hydralyte.

Abbott Laboratories (ABT): Stock With Unusual Social Activity
at The Street - Wed Apr 16, 9:18AM CDT
Trade-Ideas LLC identified Abbott Laboratories (ABT) as an unusual social activity candidate

Recall hurts Abbott, but still tops expectations
AP - Wed Apr 16, 8:56AM CDT
ABBOTT PARK, Ill. (AP) — Abbott Laboratories' first-quarter net income tumbled 31 percent on unfavorable currency exchanges and a supplier recall that lowered sales of its baby formula.

How Will This Earnings Report Affect Abbot Laboratories (ABT) Stock Today?
at The Street - Wed Apr 16, 8:53AM CDT
Abbot Laboratories (ABT) earnings report beats EPS estimates but falls short on revenue

Stock Futures In Positive Mode; Yahoo Rockets On Alibaba Boost
at Investor's Business Daily - Wed Apr 16, 7:57AM CDT
Stock futures held their early gains Wednesday, boosted by positive action overseas and despite disappointing housing market data for March. Dow futures stood a solid 84.4 points above fair market value. Nasdaq 100 futures traded up a healthy 28.7...

Abbott Reports First-Quarter 2014 Results
PR Newswire Europe - Wed Apr 16, 6:46AM CDT
- First-Quarter Ongoing EPS of $0.41, Above Previous Guidance Range of $0.34 to $0.36 (GAAP EPS from Continuing Operations of $0.22) -

Research and Markets: Global Companion Diagnostics Market 2014-2018 with Abbott Laboratories, Agilent Technologies, bioMrieux SA, Qiagen N.V. & Roche Holding Dominating
Business Wire - Wed Apr 16, 6:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/84cgmr/global_companion) has announced the addition of the "Global Companion Diagnostics Market 2014-2018" report to their offering.

Global Companion Diagnostics Market 2014-2018 with Abbott Laboratories, Agilent Technologies, bioMerieux SA, Qiagen N.V. & Roche Holding Dominating
M2 - Wed Apr 16, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3lb2g2/global_companion) has announced the addition of the "Global Companion Diagnostics Market 2014-2018" report to their offering. The Global Companion Diagnostics market will grow at a CAGR of 18.59 percent over the period 2013-2018. One of the major trends being witnessed in the market is the increase in growth strategies among vendors. Many diagnostic companies are adopting various strategies such as licensing agreements, product launches, collaborations, acquisitions, capital investment, and government support to develop companion diagnostic theranostic tests and targeted therapeutics and to strengthen their diagnostics product portfolio. Thus, many such activities are expected to boost the development of new diagnostic devices, thereby bolstering the growth of the Global Companion Diagnostics market during the forecast period. According to the report, the increased focus on cost cutting in the drug discovery and development process is one of the major drivers. The growth of genomics and proteomics has enabled the understanding of different expression stages associated with a specific disease among the human population. This has enabled many companies to develop highly specific drugs known as targeted therapeutics. It has also allowed better management of the drug development process, resulting in effective cost management. The paradigm shift in the focus to develop targeted therapeutics has enabled the development of companion diagnostic tests to monitor and administer patients with ease. Further, the report states that one of the major challenges in this market is the high cost involved in the development of companion diagnostics. The cost of developing companion diagnostics is high and adds to the overall cost of the targeted therapeutics and diagnostic tests. This report covers the present scenario and the growth prospects of the Global Companion Diagnostics market for the period 2013-2018. To calculate the market size, the report considers revenue generated from the sales of companion diagnostic tests and associated kits provided by the vendors. It also presents the vendor landscape and a corresponding detailed analysis of key five vendors in the Global Companion Diagnostics market. The market is highly fragmented, with the presence of many small and large vendors. It includes vendors that operate across the globe and have a substantial presence in North America and the European Union. In addition, the report discusses the major drivers that influence the growth of the Global Companion Diagnostics market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market. Key Vendors - Abbott Laboratories - Agilent Technologies Inc. - bioM?rieux SA - Qiagen N.V. - Roche Holding AG Other Prominent Vendors - 20/20 Genesystems Inc. - A & G Pharmaceutical Inc. - AccuTheranostics Inc. - Alacris Theranostics GmbH - AutoGenomics Inc. - Biogenex Laboratories Inc. - Leica Biosystems GmbH - Life Technologies Inc. - Luminex Corp. - pHLOGISTIX LLC - Spartan Bioscience Inc. - TheraDiag S.A. - Theranostics Health Inc. - Ventana Medical Systems Inc. Key Market Drivers/Trends/Challenges - Increasing Focus on Reducing the Cost of Drug Discovery and Development. - High Cost Associated with the Development of Companion Diagnostics. - Increase in Growth Strategies among Vendors Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/3l..._companion

Research and Markets: United States Baby Food and Formula Market 2014-2018 With Abbott Laboratories, Mead Johnson Nutrition & Nestle Dominating
Business Wire - Wed Apr 16, 4:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7twm6k/baby_food_and) has announced the addition of the "United States Baby Food and Formula Market 2014-2018 with Abbott Laboratories, Mead Johnson Nutrition & Nestle Dominating" report to their offering.

United States Baby Food and Formula Market 2014-2018 with Abbott Laboratories, Mead Johnson Nutrition & Nestle Dominating
M2 - Wed Apr 16, 3:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x33vlf/baby_food_and) has announced the addition of the "United States Baby Food and Formula Market 2014-2018 with Abbott Laboratories, Mead Johnson Nutrition & Nestl? Dominating" report to their offering. Several companies manufacturing packaged baby food are including new baby foods with variants and new flavors in their product portfolio. To differentiate their products with that of their competitors, the vendors in the Baby Food and Formula market in the US are promptly expanding their product portfolio. Organic food is considered safe for babies because it is manufactured without the use of chemicals or pesticides. Hence, many companies are introducing organic baby foods in the market to differentiate their products from other mainstream products available in the market. Companies are positioning themselves as producers of tasty, safe, and healthy food for babies. In addition, the US accounted for the largest market for organic baby food and formula products across the globe in 2013. Companies offering organic baby food such as Plum Organics are gaining a significant share in the Baby Food and Formula market in the US in recent years. Hence, the growing adoption of organic baby foods is a major trend that is expected to lead the growth of the Baby Food and Formula market in the US during the forecast period. Further, the report states that the baby food manufacturers are facing problems due to the stringent regulations introduced by the US government for the production and promotion of baby foods. The vendors in the Baby Food and Formula market in the US have to abide by the safety and quality standards in the manufacturing of packaged baby food and formula products. Key vendors dominating this space are: - Abbott Laboratories Inc - Mead Johnson Nutrition Co. - Nestl? SA. Other vendors mentioned in the report are: - Danone S.A. - Ella's Kitchen Group Ltd - Nurture Inc. (Happy Family) - H.J. Heinz Co. - Parent's Choice - Plum Organics - Sprout Foods Inc. - Stonyfield Farm Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Product - Market Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis - Business Segmentation For more information visit http://www.researchandmarkets.com/research/x3...y_food_and
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PBS Holiday Special Bets on Apollo 8, Music and Unity

Updated Category News Views 82

A moon mission, a 360-voice choir, and Christmas television make an unusual bundle, but that is precisely why this year’s Tabernacle Choir special has some real staying power. Peace on Earth: Christmas with The Tabernacle Choir is not trying to chase whatever noisy trend is chewing up attention this week. It is building a 90-minute holiday event around Apollo 8,...

Continue Reading
D-Wave Investors Face December 15 Lead Plaintiff Clock

Updated Category News Views 58

Quantum dreams met a very earthly spreadsheet problem at D-Wave this summer. The proposed securities class action against D-Wave Quantum Inc. puts a hard date on the issue for investors who bought shares between February 26 and August 25, 2026: December 15, 2026 is the deadline to seek lead-plaintiff status. That does not mean every holder needs to march into court. It...

Continue Reading
Cineverse Sets Wolf Creek Return for March 19, 2027

Updated Category News Views 121

A sunburned serial killer is heading back to theaters, and Cineverse has finally put a date on it: March 19, 2027. WOLF CRE3K, formerly called Wolf Creek: Legacy, brings John Jarratt back as Mick Taylor for the third film in the Australian horror franchise. For NASDAQ:CNVS investors, this is not the kind of announcement that lets anyone pencil in revenue with a straight...

Continue Reading
AIM Academy Accreditation Signals a Broader Quality Push

Updated Category News Views 50

Early-childhood education does not hand out many clean, easily comparable scorecards, which is precisely why AIM Academy’s new Cognia recognition deserves a closer look. The Alabama provider has earned Cognia Initial Accreditation, while its Pike Road center received Accreditation with Merit after its Initial Accreditation Review. That is not a revenue event, not a...

Continue Reading
StoneX Selloff Puts Earnings Quality Under a Harsh Lens

Updated Category News Views 111

A revenue beat can turn downright useless when the profit line springs a leak. StoneX Group delivered operating revenue above expectations and record full-year results, then watched investors hammer the stock after fiscal fourth-quarter diluted earnings per share landed at $0.66. That was $0.15 below the roughly $0.81 consensus cited in the notice, and other estimates...

Continue Reading
Childhood Nutrition Advice That Lowers Mealtime Stress

Updated Category News Views 0

A toddler surviving on three bites Tuesday is not a verdict on the family table. That plain idea sits at the center of pediatric expert Kathy Shirazi’s guidance on childhood nutrition, and frankly, it deserves more oxygen than another impossible-looking lunchbox photo. In the HelloNation article released November 20, 2026, Shirazi, MD, MPH, FAAP, urges parents to judge...

Continue Reading
FFR Adds Academic and Commercial Muscle to Its Board

Updated Category News Views 65

Robotics boards can get crowded with lofty nouns fast, and FFR just added another one with some real-world connective tissue behind it. Carolyn Kissane, associate dean at NYU's Center for Global Affairs, has joined as an independent director. The appointment is not a product launch, a contract, or revenue. It is a governance move. Still, in a business trying to weld...

Continue Reading
Art Limitless Jury Puts SDG 12 and Art Into Clear Focus

Updated Category News Views 35

A paint pigment, a discarded object, and a serious climate question have landed in the same room. BE OPEN Art’s 2026 Art Limitless competition is aimed at SDG 12, the United Nations goal centered on responsible production and consumption. That may sound like institutional language built for conference folders, but the underlying issue is plain enough: society cannot...

Continue Reading
TDH's First-Half Revenue Grew, but Margins Vanished

Updated Category News Views 106

A rental business can add tenants and still march backward, and TDH Holdings just demonstrated the ugly math. For the six months ended June 30, 2026, revenue from continuing operations rose 26.45% to $0.74 million. That is the pleasant number, and it deserves exactly one polite nod. Everything beneath it looks far less comfortable: costs climbed faster than revenue, gross...

Continue Reading
AltaPointe PATH Outreach Puts Housing Waits in Focus

Updated Category News Views 108

Two years is a brutal length of time to ask somebody without stable housing to wait for an income-based apartment. That number hangs over AltaPointe Health's PATH program in Mobile, Alabama, and it ought to. The organization helped 16 people secure permanent housing in the past fiscal year, a figure that can look small if somebody is just skimming a report. It looks very...

Continue Reading

Top 5 Most Recently Viewed Articles

European Wax Center's Inducement Grants for New Executives

Updated Category News Views 140

Overview of Inducement Grants European Wax Center, Inc. (NASDAQ: EWCZ), known as a leading provider of out-of-home waxing services across the United States, has recently made headlines with its strategic inducement grants. This move comes in light of the recent appointments of key executives, aiming to bolster the company's leadership and operational capabilities....

Continue Reading
Enhancing AI Security: Check Point and Microsoft Partnership

Updated Category News Views 283

Enhancing AI Security Through Strategic Collaboration Check Point Software Technologies Ltd. (NASDAQ: CHKP), a renowned global leader in cyber security solutions, has embarked on an exciting partnership with Microsoft. This collaboration aims to inject enterprise-grade AI security into the Microsoft Copilot Studio, ensuring that organizations can innovate safely and...

Continue Reading
TransMontaigne Partners Strengthen Credit Facility with Extension

Updated Category News Views 238

TransMontaigne Partners LLC Enhances Credit Facility Terms TransMontaigne Partners LLC has recently announced a significant development in its financial strategy. The company has officially closed Amendment No. 4 to its existing Credit Agreement, which illustrates its commitment to optimizing financial operations and enhancing financial stability. Understanding the...

Continue Reading
Red Cross Issues Urgent Call for Blood Donations Beyond Holidays

Updated Category News Views 119

Urgent Appeal for Blood Donations Post-Holiday Season The American Red Cross is currently confronting the threat of a significant blood shortage. As the busy holiday season comes to a close, blood donation rates have plummeted. Unfortunately, the rate at which blood products are being distributed now exceeds the number of donations received, raising concerns about the...

Continue Reading
Weight Loss Drugs Linked to Genetic Hair Loss in Men

Updated Category News Views 34

When weight loss turns hairy, it's not just an old wives' tale. We have some solid evidence from those eggheads at NYU Langone Health, who unearthed this hairy connection between popular weight loss drugs and the glinting domes of the genetically predisposed. Understanding the Hair-Drug Connection The name Ozempic might sound familiar, and not just because it's been...

Continue Reading